Pfizer’s RSV vaccine shows benefit in immunosuppressed adults
Pfizer said its respiratory syncytial virus (RSV) vaccine, Abrysvo, generated a strong immune response in a late-stage study of four groups of adults aged 18 years and older with a compromised immune system.
POPULAR POSTS
UK sets new climate target for 2035
November 13, 2024
Children go back to school after Valencia floods
November 13, 2024
Researchers document huge decline in African elephants
November 13, 2024
Mission: Impossible 8 title revealed
November 13, 2024
LIVE STREAM